Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : , Insitro to Collaborate on Nonalcoholic Steatohepatitis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2019 | 07:42am EDT

By Michael Dabaie

Gilead Sciences Inc. (GILD) said it will collaborate with insitro to develop nonalcoholic steatohepatitis therapies.

Under the three-year agreement, insitro's platform will be used to create disease models for NASH and discover targets that have an influence on clinical progression and regression of the disease, Gilead said Tuesday.

Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development.

Insitro will receive an upfront payment of $15 million, with additional near-term payments up to $35 million based on operational milestones. Insitro will be eligible to receive up to $200 million for the achievement of milestones for each of the five Gilead targets and up to low double-digit tiered royalties on net sales.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
05/21GILEAD SCIENCES : to Present at the Jefferies 2019 Global Healthcare Conference ..
BU
05/15GILEAD SCIENCES : Kite to Present New Data From Leading Cell Therapy Portfolio a..
BU
05/15GILEAD SCIENCES : To Donate HIV Prevention Pill Truvada To 200,000 People
AQ
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/14GILEAD SCIENCES : Statement On Inaccurate Reporting On Truvada®
PU
05/11GILEAD SCIENCES : Goldfinch to team up against kidney disease
AQ
05/10GILEAD SCIENCES : HHS chief announce donation of HIV prevention drug Truvada
AQ
05/09GILEAD SCIENCES : Drugmaker will donate meds for US push to end HIV epidemic
AQ
05/09GILEAD SCIENCES : to Provide Free Truvada for PrEP® to Support U.S. Initiative t..
BU
05/09GILEAD SCIENCES INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal..
AQ
More news
Financials ($)
Sales 2019 22 041 M
EBIT 2019 11 424 M
Net income 2019 6 929 M
Debt 2019 8 472 M
Yield 2019 3,84%
P/E ratio 2019 12,18
P/E ratio 2020 11,93
EV / Sales 2019 4,18x
EV / Sales 2020 3,76x
Capitalization 83 745 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 81,1 $
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES6.35%83 745
VERTEX PHARMACEUTICALS2.06%42 447
REGENERON PHARMACEUTICALS-17.01%32 595
GENMAB12.27%10 632
SAREPTA THERAPEUTICS INC11.05%8 718
BEIGENE LTD--.--%7 824